Christophe Demaison

Christophe is the Managing Director and CEO of ENA Respiratory, formed in 2020 as a spin-off of ENA Therapeutics Pty Ltd, now renamed Axelia Oncology Pty Ltd. He has extensive experience in start-up creation, capital raising, business and pharmaceutical product development.

He co-founded ENA Therapeutics Pty Ltd in 2006 and served until February 2021 as the Managing Director and CEO. In this role, he raised close to AU$30m from the Brandon Capital managed Medical Research Commercialisation Fund (MRCF), the Biotechnology Translation Fund (BTF) and Uniseed.

In his previous role at Melbourne Ventures and UoM Commercialisation, he led the Life Sciences Technology Commercialisation Group and was directly responsible for completing over 30 commercial IP transactions valued at over $30m (plus royalties), with local and international companies. Prior to moving to Australia, he worked in business and project management roles at Cancer Research Technology Limited (London, UK) and he was involved in Gendaq Ltd, a biotechnology company established by Nobel prize winner, Sir Aaron Klug, which was acquired by Nasdaq-listed Sangamo Biosciences Inc. Christophe has a strong research and technical background. He completed his PhD in immunology at the Pasteur Institute (Paris, France) before moving to Great Ormond Street Hospital (London, UK) where his research led in 2002 to Britain’s first successful gene therapy clinical trial for the treatment of immune deficiencies in children.